GlassScriptPhysician profile
Gerald Bruce Rosen
NPI 1942206321
$2,946.80
in general payments reported to CMS, 2019-2025
14 companies · $501 in 2025
The $501 reported for 2025 was more than what a typical Ophthalmology provider received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $526 · 2020: $125 · 2021: $271 · 2022: $686 · 2023: $448 · 2024: $388 · 2025: $501.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,338.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,337.92 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| US Retina LLC | $813.55 | 2019-2022 | |
| Alcon Vision LLC | $688.78 | 2019-2025 | Clareon, Clareon Panoptix Pro, Hydrus Microstent |
| Horizon Therapeutics Plc | $249.98 | 2023 | Tepezza |
| Dompe US, INC. | $241.14 | 2019-2025 | Oxervate |
| Johnson & Johnson Surgical Vision, INC. | $187.52 | 2022 | |
| Abbvie INC. | $167.39 | 2022-2025 | |
| Biotissue Holdings INC. | $151.95 | 2021-2025 | |
| Amgen INC. | $151.73 | 2024 | Tepezza |
| Aerie Pharmaceuticals, INC. | $121.87 | 2019 | |
| Sun Pharmaceutical Industries INC. | $87.41 | 2019-2025 | Cequa |
| Tarsus Pharmaceuticals, INC. | $39.11 | 2025 | Xdemvy |
| Bausch & Lomb Americas INC. | $17.35 | 2022 | |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $17.06 | 2019 | |
| Kala Pharmaceuticals, INC. | $11.96 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
Research and ownership
$17,869.91 in ownership or investment interests, as reported to CMS. These are holdings a clinician or an immediate family member has in a company, not payments received.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Gerald Rosen listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.